KOSDAQBiotech & Pharma380550

Neurophet

₩4,800▲ 3.34%2026-11-18 close
Market Cap
₩58.6B
Turnover
₩400M
Volume
80K
Shares out.
12.2M
PER
—
PBR
1.9×
EPS
-₩1,851
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas and Subscription Revenue Shift Is the Test Amid Losses

Neurophet's operating loss widened to KRW 16.5 billion in 2025, and expansion in the U.S. and Japan along with subscription revenue is now presented as the key to an earnings turnaround.

  1. 1

    Revenue rose 18.0% to KRW 2.62 billion in 2025, but the operating loss widened to KRW 16.5 billion.

  2. 2

    Third-quarter 2026 revenue fell 43.2% year on year to KRW 433 million, and the operating loss reached KRW 5.69 billion, larger than a year earlier.

  3. 3

    First-half 2026 revenue was KRW 1.26 billion, far below the KRW 16.5 billion full-year 2026 target presented at the 2025 listing.

  4. 4

    Neurophet raised KRW 32 billion through CPS and CB in April 2026, and cash plus short-term financial instruments were about KRW 44.9 billion at end-June 2026 according to a half-year filing report.

  5. 5

    Total equity was KRW 19.5 billion at end-2025, and operating cash flow was -KRW 15.1 billion in 2025, a larger outflow than in 2024.

02

Business structure

Neurophet, founded in 2016, is an AI brain-imaging company that runs diagnostic and treatment-support software for degenerative brain diseases such as Alzheimer's, brain electrical stimulation therapy solutions, and imaging analysis services for clinical trials.

Its key products are Neurophet AQUA, an MRI-based brain analysis software; Neurophet AQUA AD, which monitors amyloid-related imaging abnormalities (ARIA) during anti-amyloid treatment; and Neurophet SCALE PET, a PET quantification software.

The largest revenue line is Imaging CRO, a clinical-trial imaging analysis service. In first-half 2026 revenue of KRW 1.26 billion, Imaging CRO accounted for KRW 411 million, or 32.5%, the largest share, according to a report citing the half-year filing with the Financial Supervisory Service.

Combined AQUA and AQUA AD revenue was KRW 109 million in the first quarter of 2026, or 22.7% of total, and product revenue including SCALE PET was smaller than Imaging CRO that quarter, according to Medical Doctors' News.

Customer concentration is high, with two customers above 10% of first-half 2026 revenue at 19.59% and 11.11%. Overseas sales remain small, with first-half 2026 exports of KRW 53.76 million. The company says its subscription revenue share rose from 20% in 2024 to 32% in 2026, as reported by BizWatch in August 2026.

The competitive landscape is framed against domestic and global medical imaging AI companies, and the company cites its full-lifecycle solutions and pharma collaborations as differentiators.

Neurophet signed data-sharing and research collaborations with Eli Lilly and Roche, according to The Bio News' report on its 2025 listing briefing.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩800M-₩4.2B−554.2%
2025Q4₩600M-₩4.4B−774.0%
2026Q1₩500M-₩5.8B−1208.1%
2026Q2₩800M-₩5.2B−668.7%
2026Q3₩400M-₩5.7B−1313.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩2.2B-₩14.6B-₩15.1B−661.0%—−119.3%
2025₩2.6B-₩16.5B-₩22.4B−632.8%−115.1%38.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a filed basis, revenue rose 18.0% from KRW 2.22 billion in 2024 to KRW 2.62 billion in 2025. Over the same period the operating loss widened from KRW 14.6 billion to KRW 16.5 billion, and the operating margin moved from -661.0% to -632.8%.

In first-half 2026, R&D expenses were KRW 411 million, equal to 325.3% of revenue, and after government subsidies of KRW 398 million, the full amount was booked under selling and administrative expenses, according to a report on the half-year filing.

The cost base is far larger than revenue, so a higher top line has not narrowed losses. Net loss attributable to controlling shareholders widened from KRW 15.1 billion in 2024 to KRW 22.4 billion in 2025, and the net loss including non-controlling interests moved the same way.

Losses were recorded in both 2024 and 2025, and DailyHankook reported in April 2026 that the company had posted operating losses for four consecutive years. Operating cash flow went from -KRW 12.6 billion in 2024 to -KRW 15.1 billion in 2025.

Total equity at end-2025 was KRW 19.5 billion, with total liabilities of KRW 7.43 billion, and the debt-to-equity ratio moved from -119.3% in 2024 to 38.2% in 2025. The negative 2024 figure suggests equity was in negative territory that year.

Quarterly revenue went from KRW 763 million in the third quarter of 2025 to KRW 563 million in the fourth quarter (down 26.1% quarter on quarter), KRW 481 million in the first quarter of 2026 (down 14.5%), KRW 782 million in the second quarter (up 62.5%), and KRW 433 million in the third quarter (down 44.7%).

The company says its subscription base is supplemented by pharma imaging-analysis projects that can be recognized in the short term, as reported by BizWatch in August 2026, so quarterly swings in project revenue are large.

The operating loss was KRW 4.23 billion in the third quarter of 2025, KRW 4.36 billion in the fourth quarter, KRW 5.82 billion in the first quarter of 2026, KRW 5.23 billion in the second quarter, and KRW 5.69 billion in the third quarter, which is five consecutive quarters of losses on a filed basis.

Net loss attributable to controlling shareholders was KRW 6.39 billion in the third quarter of 2026, narrower than KRW 6.77 billion a year earlier, but the last four quarters total KRW 22.6 billion.

05

Industry analysis

Neurophet's demand base is brain-imaging analysis linked to the spread of anti-amyloid Alzheimer's therapies.

Domestic Leqembi prescriptions began in December 2024, and the company explained during its listing preparation that AQUA AD is used to select patients before treatment and to monitor side effects during dosing, according to DailyPharm.

The company said AQUA AD had been adopted at 31 medical institutions, including university hospitals, at that time. However, according to Medical Doctors' News, AQUA AD revenue in the first quarter of 2026 was KRW 11.89 million, about 13% of the 2025 quarterly average of roughly KRW 92.6 million.

The same report noted that false-positive detections require specialist re-review and that ARIA incidence observed in Korean patients is lower than in global trials, so the pace of paying demand is uncertain. AQUA revenue fell 4.5% from KRW 583 million in 2024 to KRW 557 million in 2025.

Overseas, reports cite Japanese health-insurance add-on fee designation in 2025, a Singapore general hospital adoption, and an exclusive distribution deal in China (The Bio News).

In market structure, Medical Doctors' News assessed in 2026 that Imaging CRO services, rather than software product sales, are what holds up revenue. Whether the therapy rollout translates into imaging-analysis demand depends on the pace of prescription growth and conversion into paid contracts.

06

Outlook

In August 2026, the company said it was pursuing new supply contracts with U.S. hospitals and imaging centers, and that some customers were reviewing product adoption (BizWatch, August 2026).

It plans to convert local contracts into subscription revenue, building a revenue base between the second half of 2026 and early 2027. A Japanese subsidiary is also under consideration for the second half of 2026, and the company is recruiting sales staff.

The company has targeted a return to operating profit in 2027, a target referenced in an April 2026 report. However, first-half 2026 revenue of KRW 1.26 billion is far short of the KRW 16.5 billion full-year 2026 target presented at the 2025 listing, according to a report on the half-year filing.

The KRW 32 billion raised in April 2026 is to be used for KRW 20 billion in R&D and KRW 12 billion in domestic and overseas sales expansion, according to the company.

An NH Investment & Securities analyst said in April 2026 that the outcome of joint research with Eli Lilly and Roche is the key variable, and that results falling short of expectations could enlarge pressure on the share price, earnings and financial burden.

Business development in Imaging CRO is another area the company said it would accelerate. Items to track are whether the U.S. supply contracts are disclosed, and the revenue growth, operating margin and subscription-revenue share in the 2026 annual report.

07

Valuation

PER
—
PBR
1.9×
ROE
-96.8%
EPS
-₩1,851
BPS
₩2,409
Dividend per share
₩0

Because the last four quarters show net losses, a price-to-earnings ratio cannot be calculated. The company pays no dividend, so comparing dividend yield with the sector carries little meaning.

The share price trades above book value, so the price-to-book ratio is the main comparison metric, and that trades at a premium to net assets. Total equity was KRW 19.5 billion at end-2025, and with an operating loss of KRW 16.5 billion in the same year, net assets shrink quickly as losses accumulate.

A half-year filing report says equity rose to the KRW 35 billion range at end-June 2026 after the April CPS and CB issuance, so the price-to-book reading is affected by financing.

Gaps between earlier earnings forecasts and actual results are wide, so a historical earnings-based multiple band is hard to use as a reference. Among sector peers, earnings-based multiples can be applied to profitable companies, while Neurophet is a loss-making company, which sets it apart.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Rising subscription revenue share

The company says its subscription revenue share rose from 20% in 2024 to 32% in 2026 (BizWatch, August 2026). Recurring subscriptions could offset swings in pharma project revenue, according to the company's reasoning. If U.S. local contracts convert into subscriptions, the revenue base would widen, per the company's plan.

Collaborations with global pharma

The Bio News reported in 2025 that Neurophet signed data-sharing and research collaborations with Eli Lilly and Roche. The company plans to accelerate business development in Imaging CRO. If collaboration results lead to product adoption or project revenue, the revenue mix could change.

Funding capacity

Neurophet disclosed that it raised KRW 32 billion through CPS and CB in April 2026. Cash and short-term financial instruments were about KRW 44.9 billion at end-June 2026 (half-year filing report). DailyHankook assessed that the funds could serve as a financial cushion until earnings generation begins.

09

Bear factors

Accumulating losses

The operating loss was KRW 16.5 billion in 2025, with an operating margin of -632.8%. The operating loss widened from KRW 4.23 billion in the third quarter of 2025 to KRW 5.69 billion in the third quarter of 2026, a larger loss year on year.

On a filed basis, the company has posted losses for five consecutive quarters from the third quarter of 2025 to the third quarter of 2026.

Revenue gap versus target

At the 2025 listing the company presented a KRW 16.5 billion full-year 2026 revenue target, but first-half 2026 revenue was KRW 1.26 billion (half-year filing report). First-half 2026 exports were KRW 53.76 million, so overseas revenue remains small.

Given the gap between target and actual results, the achievability of the company's outlook raises many open questions.

Stalled core product revenue

AQUA revenue fell 4.5% from KRW 583 million in 2024 to KRW 557 million in 2025. AQUA AD dropped from KRW 370 million in 2025 to KRW 11.89 million in the first quarter of 2026 (Medical Doctors' News).

With product revenue stalled, the reliance on Imaging CRO services to fill the gap highlights uncertainty in product growth.

10

Risk factors

Dilution and funding burden

The CPS and CB issued in April 2026 are KRW 16 billion each. DailyHankook analyzed that delayed results could heighten value dilution from repricing, potential overhang and further fundraising needs.

Because the structure includes strong investor protections, concerns have been raised that existing shareholders could bear more burden if the share price falls.

Regulation and clinical acceptance

Sisa Journal assessed that domestic results have been limited by regulatory and monetization barriers. AQUA AD has been criticized for false-positive detections that require specialist re-review.

Approvals reported in 2025 include 17 in Korea, five in the U.S. and six in Japan, but the speed at which they convert into paid contracts is a separate question.

Customer concentration and partner dependence

Two customers each accounted for more than 10% of first-half 2026 revenue, at 19.59% and 11.11%, indicating high concentration. An NH Investment & Securities analyst said in April 2026 that if joint research with global pharma falls short, earnings and financial burden could expand significantly. Project revenue swings widely from quarter to quarter, adding to forecast uncertainty.

11

What to watch next

  1. December 2026 (company plan window)

    Disclosure of supply contracts with U.S. hospitals and imaging centers, and whether revenue converts to subscriptions. This tests whether the company's plan for results between the second half of 2026 and early 2027 is being met.

  2. By March 31, 2027

    Deadline for the 2026 annual report (within 90 days after fiscal year-end). It will show annual revenue growth, operating margin, operating cash flow, and the gap to the KRW 16.5 billion full-year 2026 target.

  3. By May 15, 2027

    Deadline for the first-quarter 2027 quarterly report (within 45 days after quarter-end). It will show whether the five-quarter run of operating losses ends and whether the subscription revenue share keeps rising.

  4. Around the regular shareholders' meeting in March 2027

    The 2026 regular shareholders' meeting was held on March 30, 2026. The 2027 meeting notice may show changes to the board and to matters related to the CPS and CB.

12

Overall view

Neurophet posted KRW 2.62 billion in revenue and a KRW 16.5 billion operating loss in 2025, and the loss structure persists with a small revenue base. Third-quarter 2026 revenue of KRW 433 million fell year on year, and on a filed basis the operating loss has run for five consecutive quarters.

Positive factors include a rising subscription revenue share, data-sharing and research collaborations with global pharma, and funding secured through the April 2026 issuance.

Negative factors include first-half 2026 revenue falling far short of the listing-time target, stalled product revenue at AQUA AD and AQUA, and dilution concerns from the KRW 32 billion raise.

The 2026 annual report will show revenue growth, operating margin and operating cash flow, and disclosure of U.S. supply contracts is the first checkpoint for the subscription shift. Whether the 2027 profitability target is achieved will become clearer through these items. This report is provided for information only and does not include a buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. news.bizwatch.co.kr
  2. news.nate.com
  3. sisajournal-e.com
  4. m.news.nate.com
  5. m.dailypharm.com
  6. thebionews.net
  7. news.bizwatch.co.kr
  8. docdocdoc.co.kr
  9. sedaily.com
  10. bloter.net
  11. kr.investing.com
  12. kr.investing.com
  13. tradingkey.com
  14. m.finance.daum.net
  15. biobookmedia.com
  16. jobkorea.co.kr
  17. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis